Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Response to Finallytherock's AGM Worries
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by ronrydellon Dec 17, 2021 12:28pm
106 Views
Post# 34241053

RE:RE:RE:Response to Finallytherock's AGM Worries

RE:RE:RE:Response to Finallytherock's AGM WorriesCapitalColdwell won't give you anything...also this "Second tier" investment bank Ladenburg has been bought by a Scottsdale firm and is primarially a retail firm that owns several of the AIG broker dealer firms that flourished in the '90's. They have no equity deals on their web site but several financing deals.

If we can get a sale at fifty cents I'd take it in a heartbeat as I have'nt even got a bidder for my six figure warrants that I paid fifteen cents for (that $.15 American).. The Rock is right on....the thing that could save us are those long delayed NR's that all should be made public regarding the science improvements and upgrades. Hopefully they will finally be shared in mid January at the Bio tech conferences previously announced.

Pre Revenue deals are hardly ever accepted by investment banks...out of the 162 our firm had done...none were pre-revenue deals except a deal that we're closing that I brought to the table in the carbon fiber space.

Any takers on my warrants...you all know how to find me.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities